Idaverine, a muscarinic M2 receptor antagonist, that didn’t prevent motion sickness of cats. Clinical trials for human have shown that the compound was well tolerated.

FLUMECINOL, a benzhydrol derivative, is a hepatic microsomal drug-metabolizing enzyme inducer. It was in clinical development for the treatment of pruritus associated with primary biliary cirrhosis.

FLUFENISAL is a compound related to aspirin structurally, chemically, and pharmacologically. It was in clinical development as an analgesic and anti-inflammatory agent. However, its development was discontinued due to lack of sufficient superiority over aspirin.

PGD2 (Prostaglandin D2) is a major cellular regulator, has been shown to bind different receptors: D prostanoid receptor (DP) and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). PGD2 reportedly inhibits platelet aggregation, the proliferation of cells, and activation of neutrophils. This compound is also a potent vasodilator that also relaxes smooth muscle but causes contraction of the bronchial airways. PGD2 promotes T cell migration via CRTH2 and aggravates asthma. In contrast, there have been some studies suggesting that PGD2 exerts anti-inflammatory effects via DP, such as inhibiting the migration and activation of neutrophils, basophils, dendritic cells and T cells. Elevated levels of prostaglandin D2 (PGD2) have been shown to be present in the bald scalp of androgenic alopecia (AGA) patients and was suggested the PGD(2)-GPR44 pathway as a potential target for treatment. Also was revealed, that PGD2 might be a new target for asthma therapy, PGD2 in serum and BALF were lower in the treated group than in the untreated group.

Gloximonam (SQ-82531) is a beta-lactam antibiotic. This is a class of antibiotics that contains a beta-lactam ring in their molecular structure, such as penicillin derivatives. Gloximonam is orally absorbed and has shown anti-bacterial activity against different bacteria of the Enterobacteriaceae and Haemophilus influenzae families. Gloximonam is not effective against staphylococci and strict anaerobes (like aztreonam) and (unlike aztreonam) against Pseudomonas aeruginosa.

Hydroxystenozole is an orally active anabolic-androgenic steroid (AAS) that was described in the literature in 1967 but was never marketed.

Brocresine, an aromatic L-amino acid decarboxylase inhibitor with both a peripheral and central action was shown to potentiate the therapeutic effect of levodopa in Parkinson's disease.

Amcinafal is an anti-inflammatory agent. It is glucocorticoid corticosteroid.